Sugi Predict

Sugi Predict / Compounds / SCHEMBL9255

SCHEMBL9255

SCHEMBL9255

COc1cc(Br)cnc1N

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ HTT P42858 3/20 0.54
▸ KMT2A Q03164 2/20 0.54
▸ SHMT2 P34897 1/20 0.48
▸ POLB P06746 3/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ MET P08581 1/20 0.43
▸ FYN P06241 3/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ PDPK1 O15530 1/20 0.40
▸ MAPT P10636 1/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ TLR8 Q9NR97 1/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ IDO1 P14902 1/20 0.39
▸ DHFR P00374 1/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ CTDSP1 Q9GZU7 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL188427 0.80 KMT2A (0.50) HTTKMT2ASHMT2POLBMEN1
SCHEMBL3146860 0.80 KMT2A (0.46) HTTKMT2ASHMT2POLBMEN1
SCHEMBL15881240 0.79 MET (0.53) HTTKMT2ASHMT2POLBMEN1
SCHEMBL2616551 0.78 FYN (0.44) HTTFYNPDPK1MAPTTLR8
SCHEMBL9628 0.78 CHRNB2 (0.49) HTTKMT2ASHMT2POLBMAPT
SCHEMBL26916840 0.77 MET (0.52) SHMT2MET
SCHEMBL26916845 0.77 MET (0.52) SHMT2MET
SCHEMBL15618319 0.77 MGAM (0.52) HTTKMT2ASHMT2POLBMEN1
SCHEMBL2668576 0.77 NOS3 (0.56) FYNTLR8DHFRNPC1
SCHEMBL8916 0.77 PIK3CA (0.49) HTTKMT2ASHMT2POLBMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF RECURSION PHARMACEUTICALS INC (US) 2026-05-21 — — US disclosed
US-12612412-B2 Antiviral heterocyclic compounds ENANTA PHARMACEUTICALS, INC. (US) 2026-04-28 — — US disclosed
US-12606556-B2 TYK-2 inhibitor BEONE MEDICINES I GMBH (CH) 2026-04-21 — — US disclosed
EP-4709722-A1 ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF GENZYME CORPORATION (US) 2026-03-18 — — EP disclosed
EP-4262788-B1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME LLC (US) 2026-01-21 — — EP disclosed
US-12528822-B2 Cycloalkane-1,3-diamine derivative DAIICHI SANKYO COMPANY, LIMITED (JP) 2026-01-20 — — US disclosed
EP-4676929-A1 PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 Dark Blue Therapeutics Ltd (GB) 2026-01-14 — — EP disclosed
US-12492194-B2 HPK1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-12-09 — — US disclosed
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HUFF SARAH ELIZABETH (US) 2025-11-20 — — US disclosed
EP-4638447-A1 IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-A]PYRAZINE DERIVATIVES AS MLLT1 AND MLLT3 INHIBITORS Dark Blue Therapeutics Ltd (GB) 2025-10-29 — — EP disclosed
EP-1268443-B1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2009-07-29 — — EP disclosed
CN-101384586-A PI-3 kinase inhibitors and methods of use thereof NOVARTIS AG (CH) 2009-03-11 — — CN disclosed
EP-1989201-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE Novartis AG (CH) 2008-11-12 — — EP disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 — — WO disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 — — WO disclosed
US-6972297-B2 2-Hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM P.L.C. (GB) 2005-12-06 — — US disclosed
US-20030114674-A1 2-Hydroxy-mutilin carbamate derivatives for antibacterial use SMITHKLINE BEECHAM P.L.C. (GB) 2003-06-19 — — US disclosed
EP-1268443-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SmithKline Beecham p.l.c. (GB) 2003-01-02 — — EP disclosed
WO-2001074788-A1 2-HYDROXY-MUTILIN CARBAMATE DERIVATIVES FOR ANTIBACTERIAL USE SMITHKLINE BEECHAM PLC (GB) 2001-10-11 — — WO disclosed
US-3996352-A Acaricidal compositions of phosphoramidate esters VELSICOL CHEMICAL CORPORATION (US) 1976-12-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114674-A1 2-Hydroxy-mutilin carbamate derivatives for antibacterial use MSH6, MSH2, PMS2 HTT 242/4885KMT2A 723/4885SHMT2 1803/4885
US-12606556-B2 TYK-2 inhibitor TYK2, TXK, JAK1 HTT 1668/4885KMT2A 176/4885SHMT2 1819/4885
US-20260138956-A1 NOVEL COMPOUNDS AND USES THEREOF SLC10A1, NR3C2, CYP2C8 HTT 1821/4885KMT2A 3898/4885SHMT2 3757/4885
US-20250353841-A1 HETEROCYCLIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE HTT, HYPK, ATXN2 HTT 1/4885KMT2A 171/4885SHMT2 264/4885
US-12612412-B2 Antiviral heterocyclic compounds ZC3HAV1, NHERF1, HM13 HTT 3261/4885KMT2A 1228/4885SHMT2 1432/4885
US-12528822-B2 Cycloalkane-1,3-diamine derivative MLLT1, MLLT3, PRMT6 HTT 4310/4885KMT2A 23/4885SHMT2 1285/4885
US-12492194-B2 HPK1 inhibitors PGK1, PCK1, PDXK HTT 1471/4885KMT2A 2493/4885SHMT2 967/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.